Target intelligence / Profile preview

Adenylate kinase 2, mitochondrial (AK2)

Target
AK2
Molecular classification
Enzyme, Nucleoside monophosphate kinase, Mitochondrial protein
01

Overview

Adenylate kinase 2, mitochondrial (AK2), is an enzyme located in the intermembrane space of mitochondria. It catalyzes the reversible phosphorylation of AMP and ATP to form two ADP molecules, playing a central role in cellular energy homeostasis and adenine nucleotide metabolism. AK2 is uniquely expressed in hematopoietic progenitor cells and the inner ear. In humans, AK2 deficiency causes reticular dysgenesis, a rare and severe form of combined immunodeficiency characterized by early differentiation arrest in the myeloid lineage, impaired lymphoid development, fatal infections, and sensorineural deafness. No direct pharmacological modulators of AK2 are currently approved; the main intervention for AK2 deficiency is allogeneic hematopoietic stem cell transplantation. AK2 is classified as an enzyme, specifically a nucleoside monophosphate kinase, with essential roles in nucleotide homeostasis, mitochondrial energy transfer, regulation of apoptosis, and the differentiation of hematopoietic cells.

Other names
AK2Adenylate kinase 2Mitochondrial adenylate kinase 2Adenylate kinase isoenzyme 2Adenylate monophosphate kinaseATP-AMP transphosphorylase 2ATP:AMP phosphotransferaseTestis secretory sperm-binding protein Li 220n
02

Mechanism of action

No validated therapeutic drugs with a defined mechanism directly target AK2; gene therapy or hematopoietic stem cell transplantation are treatment approaches for related deficiency, not small-molecule inhibition or activation.

03

Biological functions

Cellular energy homeostasisAdenine nucleotide metabolismRegulation of apoptosisHematopoietic progenitor cell differentiationMitochondrial energy transfer
04

Disease associations

Severe combined immunodeficiency (SCID) (specifically reticular dysgenesis)Hematopoietic defectsSensorineural deafness(Potential) Oncogenesis(Potential) Hemolytic anemia
05

Safety considerations

Hematopoietic toxicity (AK2 deficiency leads to severe immunodeficiency)Mitochondrial dysfunction (altered energy metabolism affects multiple organ systems)Sensorineural hearing loss (associated with AK2 deficiency)
06

Biomarkers

AK2 protein deficiency in bone marrow progenitors (diagnostic marker for reticular dysgenesis)AK2 genetic mutation (used in genetic diagnosis of SCID subtypes)

Beyond the preview

Go deeper on Adenylate kinase 2, mitochondrial (AK2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adenylate kinase 2, mitochondrial (AK2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call